Notable Recent Publications

These are some recent publications which give a flavour of the research from the Barclay lab. For a complete list of publications, please see below.

Species difference in ANP32A underlies influenza A virus polymerase host restriction. Nature (2016).
Jason S. Long, Efstathios S. Giotis, Olivier Moncorgé, Rebecca Frise, Bhakti Mistry, Joe James, Mireille Morisson, Munir Iqbal, Alain Vignal, Michael A. Skinner & Wendy S. Barclay

This paper identified a key factor that explained why the polymerases from avian influenza viruses are restricted in humans.  For more, please see the associated New and Views.

See our latest ANP32 papers here: eLIFE, Journal of Virology, Journal of Virology.

The mechanism of resistance to favipiravir in influenza. PNAS (2018).
Daniel H. Goldhill, Aartjan J. W. te Velthuis, Robert A. Fletcher, Pinky Langat, Maria Zambon, Angie Lackenby & Wendy S. Barclay

This paper showed how influenza could evolve resistance to favipiravir, an antiviral that may be used to treat influenza. The residue that mutated to give resistance was highly conserved suggesting that the mechanism of resistance may be applicable to other RNA viruses.

Internal genes of a highly pathogenic H5N1 influenza virus determine high viral replication in myeloid cells and severe outcome of infection in mice. Plos Path. (2018).
Hui Li*, Konrad C. Bradley*, Jason S. Long, Rebecca Frise, Jonathan W. Ashcroft, Lorian C. Hartgroves, Holly Shelton, Spyridon Makris, Cecilia Johansson, Bin Cao & Wendy S. Barclay

Why do avian influenza viruses like H5N1 cause such severe disease in humans? This paper demonstrated that H5N1 viruses replicate better than human viruses in myeloid cells from mice leading to a cytokine storm and more severe disease.

Citation

BibTex format

@article{Lindsey,
author = {Lindsey, BB and Singanayagam, A and Tregoning, JS and De, Silva T and Barclay, W},
journal = {Lancet Respiratory Medicine},
title = {The impact of an updated pandemic H1N1 strain on shedding and immunogenicity to Russian-backbone live attenuated influenza vaccine among children in The Gambia: an open-label, observational, phase 4 study},
url = {http://hdl.handle.net/10044/1/68667},
}
Download

RIS format (EndNote, RefMan)

TY  - JOUR
AB  - Background: Poor efficacy and effectiveness of thepandemic H1N1 (pH1N1) component inlive attenuated  influenza  vaccine  (LAIV)has  been  demonstrated  in  several  studies.The  reasons  for this are unclear, butmay be due toimpairedreplicative fitness of pH1N1 A/California/07/2009-like (Cal09) strains.  The aim of this study was to establish whether an updated pH1N1 strain in the Russian-backbone trivalent LAIV resulted in greater shedding and immunogenicitycompared to Cal09.Methods: In an open-label, prospective,observational,phase 4study, we evaluated the impact of updating the pH1N1 component in the WHO prequalified Russian-backbone trivalent LAIV from Cal09in 2016-17(n=118) to an A/Michigan/45/2015-like strain (A/17/New York/15/5364, NY15) in 2017-18(n=126),on  shedding  and  immunogenicity  in  Gambian  children  aged  2-4  years  old.The  study  was  nested  within  a  randomised  controlled  trial  investigating  LAIV-microbiome interactions (ClinicalTrials.gov NCT02972957). Findings: Cal09  showed  impairednasopharyngeal  shedding(13.6%children  shedding at  day  2 post-LAIV)compared to H3N2(45.8%)and influenza B(80.5%), along with sub-optimal serum antibody(5.1%seroconversion)and T-cell  responses(40.5% CD4+IFN-g+ and/or  CD4+IL-2+responders).  Following  the  switch  to  NY15,  a  significant  increase  in pH1N1 shedding(63.5%)was  seen, along with  improvements  in seroconversion(19.1%)and  influenza-specific  CD4+  T-3cell responses(65.7%). The improvement in pH1N1 seroconversion with NY15 was even greater in  children  seronegative  at  baseline(37.5%  vs.  7.6%). Persistent  shedding today 7was independently  associated  with  both  seroconversionand  CD4+  T  cell responsein  multivariable logistic regression. Interpretation:The  pH1N1  component  switch  may  have  overcome  problems  in  prior LAIV formulations.LAIV effectiveness against pH1N1 shouldtherefore improve in upcoming influenza seasons. Our  dataalso highlightthe  importance  of  evaluat
AU  - Lindsey,BB
AU  - Singanayagam,A
AU  - Tregoning,JS
AU  - De,Silva T
AU  - Barclay,W
SN  - 2213-2600
TI  - The impact of an updated pandemic H1N1 strain on shedding and immunogenicity to Russian-backbone live attenuated influenza vaccine among children in The Gambia: an open-label, observational, phase 4 study
T2  - Lancet Respiratory Medicine
UR  - http://hdl.handle.net/10044/1/68667
ER  -
Download

Contact us

For any enquiries related to this group, please contact:

Professor Wendy Barclay
Chair in Influenza Virology 
+44 (020) 7594 5035
w.barclay@imperial.ac.uk